Multisystem Inflammatory Syndrome in Children (MIS-C):
Deepika Thacker
Abstract
As the world came to terms with the current COVID-19 pandemic, children were initially thought to have milder disease than adults with significantly lower morbidity and mortality. The emergence of a multi-system inflammatory syndrome in children (MIS-C) associated with the SARS-CoV-2 virus was first recognized in Europe, and then across centers in the United States. Early and widespread data sharing among centers across the world was extremely helpful in early identification and treatment of these children, with a good prognosis in a majority of cases. Significant research is required to answer several questions that have been raised, including susceptibility, long-term effects, and pathogenesis and treatment options to name a few.